ETRA.US Electra Therapeutics, Inc. Common stock
- Market cap
- USD 555M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ETRA.US undervalued?
Graham numberThe Graham number of Electra Therapeutics, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Electra Therapeutics, Inc. Common stock fundamental analysis
No fundamental analysis for Electra Therapeutics, Inc. Common stock yet.
Electra Therapeutics, Inc. Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Electra Therapeutics, Inc. Common stock
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Maligna…
Full company profileElectra Therapeutics, Inc. Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Electra Therapeutics, Inc. Common stock annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | 0.00 | 0.00 | - |
| Operating Income | -26.3M | -61.9M | -100K |
| EBITDA | -24.8M | -60.5M | -100K |
| Net Income | -24.8M | -62.0M | -97.8K |
| EPS | -0.39 | -1.80 | -2,223 |
| Balance Sheet | |||
| Total Assets | 19.4M | 99.4M | 106M |
| Total Liabilities | 123M | 130M | 133M |
| Shareholders' Equity | -103M | -30.3M | -26.8M |
| Cash & Short-term Investments | 14.8M | 86.5M | 97.7M |
| Total Debt | - | 2.09M | 1.98M |
| Cash Flow | |||
| Operating Cash Flow | -26.0M | -60.5M | -77.8K |
| Capital Expenditure | 0.00 | 733K | 54.00 |
| Free Cash Flow | -26.0M | -61.2M | -77.8K |
| Ratios | |||
| ROA | -127.6% | -62.4% | -0.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Electra Therapeutics, Inc. Common stock dividends
Electra Therapeutics, Inc. Common stock has not paid dividends in the last 2 fiscal years.
Who owns Electra Therapeutics, Inc. Common stock
- Insiders 5.29%
- Institutions 61.94%
- Public & others 32.78%
- Shares outstanding 62.8M
- Free float 24.9M
Top funds holding ETRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| HBM Healthcare Investments AG Ord | 2.48M | 3.95% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Growth A | 960K | 1.53% | 0.00% | Sep 2026 |
| AB Small Cap Growth A | 764K | 1.22% | 0.00% | Sep 2026 |
| PGIM Jennison Health Sciences Z | 499K | 0.80% | 0.00% | Sep 2026 |
| T. Rowe Price Small-Cap Value | 412K | 0.66% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Blend A | 307K | 0.49% | 0.00% | Sep 2026 |
| Victory Science & Technology | 260K | 0.41% | 0.00% | Sep 2026 |
| Principal SmallCap Growth I Instl | 240K | 0.38% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 137K | 0.22% | 0.00% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 128K | 0.20% | 0.00% | Sep 2026 |
| JPM US Small Cap Growth A dist USD | 106K | 0.17% | 0.00% | Sep 2026 |
| Victory RS Small Cap Growth A | 96.3K | 0.15% | 0.00% | Sep 2026 |
| JPM US Small Cap Growth C Acc | 72.9K | 0.12% | 0.00% | Sep 2026 |
| Victory RS Science and Technology A | 66.7K | 0.11% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 15.8K | 0.03% | 0.00% | Sep 2026 |
| AB VPS Small Cap Growth A | 15.4K | 0.02% | 0.00% | Sep 2026 |
| Bayview US Bio Venture MF | 14.7K | 0.02% | 0.00% | Sep 2026 |
| Franklin Alternative Strategies R6 | 11.1K | 0.02% | 0.00% | Sep 2026 |
| T. Rowe Price Health Care ETF | 10.2K | 0.02% | 0.00% | Oct 2026 |
| Federated Hermes Managed Volatility II P | 10.0K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding ETRA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Sanofi | 2.46M | 3.92% | 0.00% | Sep 2026 |
Electra Therapeutics, Inc. Common stock company profile
- Company name
- Electra Therapeutics, Inc. Common stock
- Ticker
- ETRA.US
- Exchange
- USA Stocks
- Listed since
- Sep 18, 2026
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- 230 E Grand Avenue, South San Francisco, CA, United States, 94080
- Phone
- (888) 743-2290
- Website
- electra-therapeutics.com
About Electra Therapeutics, Inc. Common stock
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
Electra Therapeutics, Inc. Common stock management
6- Dr. Quehuong Dong M.B.A., Pharm.D.President, CEO & Director · born 1982
- Mr. Gary S. Koe Ph.D.Chief Technology Officer · born 1964
- Dr. Kim-Hien Dao D.O., Ph.D.Chief Medical Officer · born 1973
- Mr. Christopher William Clark C.F.A.Chief Financial Officer · born 1978
- Mr. David J. TuckerSenior VP of Finance & Principal Accounting Officer · born 1968
- Dr. Graham Parry Ph.D.Chief Scientific Officer · born 1964